Applications of Cimetidine Hydrochloride in Industrial Manufacturing

As a direct manufacturer of Cimetidine Hydrochloride, we supply this active pharmaceutical ingredient (API) for specific industrial and pharmaceutical production scenarios where quality assurance, regulatory compliance, and controlled formulation are critical. Our commitment extends from raw material processing to technical support for downstream producers in highly regulated industries.

1. Formulation of Oral Solid Dosage Pharmaceuticals (Tablets and Capsules)

Cimetidine Hydrochloride serves as a key active ingredient in the manufacture of prescription and over-the-counter solid dosage forms for gastric acid-related disorders. Pharmaceutical formulators incorporate it during the blending phase, ensuring homogenous dispersion in excipient matrices. Stringent in-process controls align with pharmacopeia specifications, and batch records detail precise usage ratios adjusted for desired dosage strength. Finished products include coated and uncoated tablets, as well as hard gelatin capsules, which are distributed through hospital and retail channels after undergoing rigorous release testing.

Industry compliance standards

• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur)
• Japanese Pharmacopoeia (JP)
• China National Medical Products Administration (NMPA) GMP for APIs and Finished Dosage Forms

Typical usage ratio

• 20-50% w/w in final blend, depending on strength (e.g., 200 mg, 400 mg tablets); formulated with excipient adjustments for tablet hardness and disintegration

Downstream process integration

• Dry or wet granulation stage, blended with fillers and disintegrants prior to tableting or capsule filling

Final product types

• Prescription tablets (e.g., 200 mg, 400 mg)
• OTC gastric acid reducer tablets
• Hard gelatin capsules for hospital distribution

2. Production of Parenteral Preparations (Injectables)

In sterile manufacturing environments, downstream injectable formulators use the monohydrochloride salt for reconstitution and solution preparation. Its solubility supports high-purity IV and IM injection formats indicated for acute gastric acid secretion management. Producers rely on advanced aseptic processes, including terminal sterilization and filtration, to comply with injectable drug requirements. Batch release is predicated upon meeting microbiological and physicochemical criteria established by regulatory authorities.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP) per 21 CFR Parts 210 and 211
• USP <797> Pharmaceutical Compounding – Sterile Preparations
• European Pharmacopoeia Parenteral Standards
• World Health Organization (WHO) GMP for Sterile Products

Typical usage ratio

• 10-25 mg/mL in finished injectable solutions; concentrations tailored based on target administration route and product labeling

Downstream process integration

• Dissolved in purified water during compounding; processed via sterilizing filtration (0.22 μm) before filling into ampoules or vials

Final product types

• Sterile injection ampoules
• Single-use vials for hospital and emergency use

3. Manufacturing of Veterinary Pharmaceuticals

Cimetidine Hydrochloride extends to the production of veterinary medicaments targeting ulcer management in companion animals, particularly in formulations adapted for oral administration. Regulatory guidance for veterinary APIs necessitates compliance with both animal-specific GMPs and MRLs (maximum residue limits) to ensure safety. Dosage forms often account for species-specific pharmacokinetic considerations.

Industry compliance standards

• Veterinary Good Manufacturing Practices (VGMP) as stipulated by regulatory bodies (e.g., FDA CVM in the USA, EMA CVMP in EU)
• Codex Alimentarius residue limits
• Pharmacopoeia monographs for veterinary substances

Typical usage ratio

• 15-25% by weight in oral veterinary pastes or suspensions, adjusted according to target animal weight and administration frequency

Downstream process integration

• Premixed with palatable carriers, suspended in aqueous media or blended with flavor-enhanced bases prior to homogeneous dispensing into syringes or bottles

Final product types

• Oral veterinary pastes (e.g. for horses, cats, dogs)
• Liquid suspensions for animal clinics
• Veterinary oral tablets

4. Compounding Pharmacies (Hospital and Clinical Preparations)

Hospital and institutional compounding pharmacies rely on pharmaceutical-grade Cimetidine Hydrochloride for on-demand preparation of non-commercial dosage forms, especially intended for patients with unique dosing requirements or administration needs such as pediatric or feeding tube patients. Compounding requires strict adherence to documented monographs and is typically batch-prepared under supervision of licensed pharmacists, with source material traceability mandated.

Industry compliance standards

• USP <795> Pharmaceutical Compounding – Nonsterile Preparations
• USP <797> for sterile preparations, where applicable
• National Association of Boards of Pharmacy (NABP) Model State Pharmacy Act

Typical usage ratio

• 5-20% w/v in oral suspension bases or as specified in individualized compounding formulas according to patient prescription

Downstream process integration

• Manual dissolution or levigation into chosen vehicles, typically prepared in controlled environments with in-process pH and analytical confirmation

Final product types

• Oral suspensions for pediatric, geriatric, or tube-fed patients
• Topical preparations for clinical trial or compassionate use

5. Bulk API Supply for Licensed Pharmaceutical Manufacturers

Downstream finished dosage manufacturers source Cimetidine Hydrochloride as a GMP-compliant active component for registering and launching new or generic anti-ulcer medications globally. API integration begins at regulatory documentation and DMF referencing, proceeding through validation and commercial-scale blending. Consignment batches must meet multi-jurisdictional standards, and all documentation supports traceability from raw material intake through market release.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• EU GMP Part II for APIs
• US FDA Drug Master File (DMF) requirements
• Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP)

Typical usage ratio

• Varies based on target finished product formulation (typically 10-50% API load in final blend), dosage strength, and process scale

Downstream process integration

• Integrated at primary blending or granulation stage for both direct compression and wet granulation processes, with in-process standardization and analytical release

Final product types

• Generic and brand prescription pharmaceuticals
• Export formulations for regulated and semi-regulated markets